Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Areas served: Medically reviewed by Dr
(A) GLP-1 can induce fibronectin type III domain-containing protein 5 (FNDC5) expression in pancreatic -cells through the interaction of its downstream transcription factor cAMP-response element binding protein (CREB) with binding elements in the FNDC5 promoter, thereby promoting the conversion of white adipose tissue (WAT) to brown adipose tissue (BAT)
In 2014, the drug was approved for weight loss under the brand name Saxenda
For 32 weeks, half of the participants were given a placebo shot once per week, while the other half got active semaglutide jabs
Commercial insurance coverage for GLP-1 weight-loss medications has expanded in 2024-2026 - many large employers added coverage - but coverage remains uneven and typically requires prior authorization for obesity indications
Since semaglutide was originally developed to help people with type 2 diabetes manage blood sugar, its designed for ongoing use as a treatment for chronic health conditions
